6.1.2 WILLOW study (phase II clinical trial) 6.1.2.1 Study design and population The WILLOW study represented a pivotal Phase II clinical trial of brensocatib in bronchiectasis patients ( The study recruited 416 patients total, with 256 patients meeting inclusion criteria completing randomization, allocated to placebo group (87 patients), 10 mg brensocatib group (82 patients), and 25 mg brensocatib group (87 patients)
It suggests the company has experience working with the types of delivery systems, textures, and packaging formats that serum products require
Statistical analysis of high-dimensional biomedical data: a gentle introduction to analytical goals, common approaches and challenges
Clinical studies show that approximately 2550% of lost weight returns within one year after stopping tirzepatide, with some patients regaining all weight within 18 months
FDA approvals are increasing Medicare coverage, but it is still a long way from covering all recipients with obesity
GLP-1, is one of the major incretin hormones produced in the intestinal L-cells
